Zacks Research Issues Pessimistic Forecast for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Research analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, May 18th. Zacks Research analyst D. Bautz now expects that the biopharmaceutical company will post earnings per share of ($0.25) for the quarter, down from their prior forecast of ($0.14). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.73) per share. Zacks Research also issued estimates for Abeona Therapeutics’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.96) EPS.

Several other equities research analysts have also recently commented on the company. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a research note on Tuesday, March 17th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Finally, Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.00.

Abeona Therapeutics Trading Up 3.9%

ABEO stock opened at $5.32 on Thursday. The business has a fifty day moving average price of $5.11 and a 200 day moving average price of $5.05. Abeona Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $7.54. The stock has a market capitalization of $303.19 million, a price-to-earnings ratio of 5.48 and a beta of 1.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.89 and a quick ratio of 5.70.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new position in Abeona Therapeutics in the second quarter valued at about $27,000. Royal Bank of Canada grew its stake in Abeona Therapeutics by 49.6% in the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 2,155 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Abeona Therapeutics in the third quarter valued at about $37,000. Truvestments Capital LLC lifted its holdings in shares of Abeona Therapeutics by 191.4% in the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $57,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Eric Crombez sold 26,143 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $5.53, for a total value of $144,570.79. Following the completion of the transaction, the director directly owned 37,313 shares of the company’s stock, valued at approximately $206,340.89. The trade was a 41.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Madhav Vasanthavada sold 5,548 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $5.96, for a total value of $33,066.08. Following the completion of the transaction, the insider directly owned 313,071 shares of the company’s stock, valued at approximately $1,865,903.16. The trade was a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.